Nilotinib
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Nilotinib for First-line Newly Diagnosed CML-CP Patients (NCT03942094) | Shenzhen Second People's Hospital | 2019-06-01 |
| Tasigna in Glivec-resistant or Intolerant Patients in CML (NCT01206088) | Novartis Pharmaceuticals | 2009-02-01 |
Track Nilotinib automatically
Every clearance here is in the API, with alerts when new ones post.